Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
Cupid has been allocated approximately 23.4 million units of female condoms per year
From material selection to cooling tower management, every small decision affects long-term equipment reliability
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Subscribe To Our Newsletter & Stay Updated